Objective: Two chromosomal instability (CIN) pathways are described in glioblastoma multiforme (GBM), type 1 and type 2, which can be observed in up to 70% of the cases. Microsatellite instability (MSI) plays a pathogenic role in sporadic cancers such as colon, gastric and endometrial carcinomas with deficient mismatch repair (MMR). We aimed to perform a comprehensive analysis of the relationship between CIN and MSI mechanisms in sporadic glioblastomas. Methods: 129 GBMs were examined (109 newly diagnosed and 20 relapses) investigating MSI, immunohistochemical expression of MMR proteins as well as sequencing and promoter methylation of hMLH1. We characterized the molecular changes frequently correlated with CIN in MSI+ GBMs and compared them with 26 microsatellite-stable tumors. Results: Low-level MSI was observed in 11 of 129 (8.5%) cases and was higher in relapses than in primary GBMs (25 vs. 5.5%, p = 0.027). High-level MSI was not found in any case. A deficient expression of MLH1 and PMS2 without hMLH1 inactivation was observed only in one giant cell GBM. 55% of the MSI+ GBMs showed a profile which did not correspond to one of the known CIN pathways. An inverse association was observed between MSI and mutations of both p53 and PTEN. Conclusions: Our data suggest that CIN and MSI contribute to the genomic instability in GBMs via independent pathways. Since MSI was significantly more frequent in relapses, it might play a role in the malignant progression of GBM.
A second form of genomic instability, microsatellite instability (MSI), typically displays length mutations in microsatellite sequences in noncoding and in coding regions of genes such as PTEN, TGFßR-II, IGFIIR, BAX and E2F4 [12] [13] [14] [15] . MSI was suggested to be the consequence of the inactivation of mismatch repair (MMR) genes [12, 13, 16] and was observed in hereditary syndromes, i.e. hereditary nonpolyposis colorectal cancer (HNPCC) with a frequency of up to 90% [13, 16] , and sporadic malignancies such as colorectal (15%) [17] , endometrial (15%) [18] , non-small-cell lung (35%) [19] , head and neck (28%) [20] , gastric (10%) [21] or prostate cancers (8.5%) [22] . In sporadic tumors, MSI was found to be most frequently caused by hMLH1 promoter hypermethylation [23] . The relevance of MSI in sporadic cancers is confirmed by molecular and clinicopathological observations such as an inverse relationship between MSI and p53 mutations in gastric cancer [19] and colorectal cancer cell lines [24] , the association of MSI with the malignant progression in gastric tumors [25] and metastatic gastric cancers [26] or the distinct histopathological features of MSI+ colorectal cancer compared to their MSS (microsatellite-stable) homologues [27] .
A comprehensive analysis of the molecular basis of MSI and the relationship with the CIN-mediated pathways has not been performed in glioblastoma. MSI was described in GBM in some previous studies but either small tumor series are available or only few polymorphic repeats were used. Therefore, we investigated 129 sporadic GBMs for MSI using 15 polymorphic repeats and performed immunohistochemistry for the MMR proteins hMLH1, hPMS2, hMSH2 and hMSH6, mutational analysis of hMLH1 as well as evaluation of hMLH1 promoter methylation. To elucidate the (in)dependence of MSI and the CIN, we carried out loss of heterozygosity (LOH) studies at loci involved in GBM pathogenesis, mutational screening of p53 and PTEN and investigated EGFR amplification in both MSI and MSS tumors.
Material and Methods

GBM Samples
129 paired samples of blood and tumor tissue were obtained from GBM patients treated at the Department of Neurosurgery of the University of Dresden. Portions of the fresh tumor samples were frozen in liquid nitrogen and stored at -80°C. Tumor tissue was evaluated at the Institute of Pathology, University of Dresden, Germany, according to the World Health Organization (WHO) criteria [3] . Formalin-fixed, paraffin-embedded specimens were used for immunohistochemistry. Leukocyte and tumor DNA were isolated applying the QIAamp ® DNA Mini Kit (Qiagen, Hilden, Germany). This study was conducted with the consent of the institutional ethics committee and an informed consent from each patient or his/her caretaker was obtained.
MSI Analysis
Matched genomic tumor and blood DNA were amplified by PCR using 15 primer pairs [28, 29] : mononucleotides (BAT25, BAT26, BAT40, TGß-RIIpA, GTBPIn5, GTBPIn9), dinucleotides (D5S346, D17S250, D10S197, D2S123, D18S58, D13S153, D3S1300, D3S1619) and a tetranucleotide (MYCL1). PCR was performed using 50-100 ng of template DNA. Amplified PCR products were electrophoresed on a 6.5% Long Ranger polyacrylamide gel on an Automated Laser Fluorescence (ALF express ® ) sequencing device (Amersham Pharmacia Biotech, Freiburg, Germany) and analyzed using the ALLELELINKS ® 1.00 software (Amersham Pharmacia Biotech). MSI was defined by the presence of novel alleles in tumor DNA that were absent in corresponding leukocyte DNA [30] and confirmed in two independent analyses. Informative dinucleotide repeats without MSI were assessed for LOH as described [31, 32] . Three categories were defined according to the MSI findings: highlevel MSI (MSI-H, 640% of studied loci altered), low-level MSI (MSI-L, ! 40%) and MSS (no analyzed marker unstable) [27, 28, 33] .
Immunohistochemistry of MMR Proteins
Immunostaining for hMLH1 (clone G168-15, PharMingen Int., San Diego, Calif., USA), hMSH2 (clone FE11, Oncogene Res. Products, Cambridge, Mass., USA), hMSH6 (clone 44, Transduction Lab., Lexington, UK) and hPMS2 (A16-4, PharMingen Int., San Diego, Calif., USA) was performed in all MSI+ tumors as described [34] . Tumor cells exhibiting no or reduced nuclear staining were considered as having an abnormal pattern. The relative densitometry of MMR protein expression (compared to the negative controls) was performed using the Meta-Vue ® software (Universal Imaging Systems, Downingtown, Pa., USA).
Mutational Analysis of hMLH1, p53 and PTEN We sequenced all coding exons and exon-intron boundaries of hMLH1, p53 and PTEN from leukocyte and tumor DNA. After PCR amplification, the products were electrophoresed in 0.8% agarose gel and subjected to cycle sequencing reactions using the Thermo Sequenase ® Fluorescent Cycle Sequencing kit (Amersham Pharmacia Biotech). After denaturation, the cycle-sequencing products were resolved using a denaturing 6.5% Long Ranger polyacrylamide gel on a sequencing device. Primer sequences and amplification conditions were described elsewhere and are available from the authors [35] [36] [37] .
Methylation Status of the hMLH1 Promoter Region
Leukocyte and tumor DNA were digested with methylation-sensitive or insensitive restriction endonucleases, HpaII (Life Technologies, Karlsruhe, Germany) or MspI (New England Biolabs, Frankfurt am Main, Germany), respectively. After digestion of 250 ng of genomic DNA, 25 ng from each digest was used as the template for PCR amplification of an 829-bp fragment which contains the promoter region, the exon 1 and a part of the intron 1 of the hMLH1 and harbors five HpaII sites. The amplification products were visualized using a 1% agarose gel. Primer sequences and PCR conditions were described previously [23] . The breast cancer cell line CAL51 was used as positive control [38] . 
LOH Analysis and Semiquantitative PCR Analysis of EGFR
Amplification LOH at 10q23-24 was studied with the markers D10S215 and D10S541 (flanking PTEN), PTENCA (PTEN intragenic marker), D10S583 and D10S579 (telomeric and centromeric to PTEN, respectively). Analysis of LOH at 17p13 (p53) was done with the TP53 and a p53 intragenic marker. Allelic losses at 9p21 (p16/CDKN2A, p14 ARF and p15/CDKN2B) and 13q14 (RB1) were studied with the primers D9S1748, D9S171, D9S1749, D13S153 and D13S267, respectively. LOH at 1p35-36 and 19q13 was assessed with the markers D1S468, D1S482, D19S112 and D19S412 [39, 40] . Primer sequences and PCR amplification conditions are based on Genome Database entries (www.gdb.org). To detect EGFR amplification a differential PCR with the cystic fibrosis transmembrane regulator (CFTR) gene was carried out, as previously described [40] .
Statistical Analysis
Contingency analyses between variables were performed using a two-tailed Fisher's exact test and a t test. The relationship between MSI and other variables was evaluated by multiple regression analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were obtained through logistic regression. A value of p ! 0.05 was considered to be statistically significant.
Results
109 newly diagnosed GBMs and 20 relapses were analyzed. Sixteen of the 109 newly diagnosed GBM patients suffered from a previous lower grade astrocytoma (WHO grades II and/or III). A further 7 patients had a survival time of more than 36 months after surgery (long-term survivors). Only 4 patients had a personal history of cancer (3 colorectal carcinoma and 1 breast cancer). There was no family history of cancer in any of the cases. Detailed clinical data of the patients are presented in table 1.
MSI Status
The total MSI rate was 8.5% (11/129 patients). Lowlevel MSI was evidenced in 6 of 109 newly diagnosed GBMs (5.5%) and in 5 of the 20 relapses (25%) ( fig. 1 ). MSI-H was not observed. Fourteen of the 1,007 evaluable dinucleotides (1.4%) and 2 out of 120 evaluable tetranucleotides (1.7%) were unstable. None of the 11 MSI+ tumors showed instability of the mononucleotide repeats. The most sensitive markers were D5S346 (4/16 unstable markers), D13S153 (3/16 unstable repeats) and D3S1619 (2/16 instability cases). A statistically significant association between MSI and any of the analyzed markers was not found.
The MSI rate in patients older than 55 years was 9.5% (this cut-off level showed the lowest p value), and 4.4% in patients younger than 55 years (p = 0.26). There were no significant associations between gender and the MSI status (p = 0.21).
The presence of MSI in relapsed GBMs was significantly higher (p = 0.0274, 95% CI) than in newly diagnosed tumors. MSI was more frequently detected in glioblastoma patients with a previous low-grade astrocytoma than in those with clinically de novo glioblastomas (12.5 vs. 6.5%, p = 0.15). showed no amplification of the promoter fragment (829 bp) of hMLH1, indicating no methylation of the 5 cytosine residues within the CpG islands of the 5 restriction sites within the fragment. Leukocyte DNA (B5) from the patient was also analyzed. As negative control (NC) we used leukocyte DNA from a healthy Caucasian adult. The breast cancer cell line CAL51, which was previously observed to harbor hMLH1 promoter hypermethylation, was used as positive control. U and W stand for undigested DNA and water, respectively. 
Immunohistochemical Studies
Analysis of the Sequence and Promoter Methylation of hMLH1
By sequencing the 19 coding exons and flanking intron boundaries of the hMLH1 in the giant cell GBM with reduced hMLH1 expression, neither germline nor somatic genetic alterations were detected. No hMLH1 promoter fragment appeared from either tumor DNA or constitutional DNA after HpaII digestion, ruling out a hypermethylation of the 5 tested cytosine residues in the promoter region of hMLH1 ( fig. 1) .
Analysis of the CIN-Mediated Pathways
We examined tumor and leukocyte DNA from 37 patients, 11 MSI+ and 26 MSS GBMs as controls. In MSI+ glioblastomas, the sequence analysis of p53 evidenced alterations only in one tumor, a giant cell GBM (1/11, 9%). Two single base pair exchanges were observed on exon 5 in codon 175 (CGC→CAC) and exon 6 in codon 199 (GGA→AGA), predicting the substitution of histidine for arginine and arginine for glycine, respective- Martinez/Schackert/Plaschke/Baretton/ Appelt/Schackert ly. In this patient, LOH at 17p13 was observed as well. Two further MSI+ GBMs showed LOH at 17p13 without p53 sequence alterations. In MSS tumors we detected mutations of p53 more frequently (7/26, 27%), including 6 single base pair exchanges on exons 2, 4 and 8, which predicted amino acid substitutions in 5 cases as well as one deletion on exon 7 (nt 13316_13321delAACAGT). Table 2 shows the results of the analyses of CIN pathways in both MSI and MSS GBMs.
Concerning PTEN, mutations in MSI+ GBMs were observed in 2 cases (2/11, 18%) on exon 5. In MSS glioblastomas, mutations of PTEN were detected in 12 of 26 cases (46.2%), consisting in 10 base pair exchanges on exons 2, 5, 6 and 7, predicting amino acid substitutions in 8 cases. Two acceptor splice site heterozygous mutations on exon 9 (IVS9-2A1G) were observed as well. The rates of PTEN mutations were higher in both MSS primary and MSS relapses compared with primary and relapse MSI+ tumors (38 vs. 14%, p = 0.18 and 54 vs. 25%, p = 0.2, respectively). LOH at 10q23-24 was found in MSI+ and MSS GBMs in 72 and 80.7%, respectively.
The EGFR/CFTR ratios of the 11 MSI+ glioblastomas are displayed in table 3. The cut-off level for a normal gene copy number (x+3SD) was 3.91. Four of 11 MSI+ GBMs and 12 out of 26 MSS tumors (36.4 and 46.2%, respectively) showed ratios 13.91, thus indicating amplification of the EGFR oncogene. In recurrences, amplification of EGFR was more frequent in MSI+ tumors than in MSS GBMs (60 vs. 38%, p = 0.25). In contrast, in primary glioblastomas we detected a higher rate of EGFR amplification in MSS tumors than in MSI+ GBMs (53.8 vs. 16 .7%, p = 0.15).
Discussion
The MMR genes play an important role in maintaining the genetic stability of DNA. Inactivation of these genes may lead to a mutator phenotype, which has been proposed to promote accumulation of alterations in oncogenes and tumor suppressor genes [12, 13] . This mutator phenotype has been observed in HNPCC-associated MSI-H malignancies as well as in sporadic tumors harboring distinct molecular features [26, 27] . Furthermore, sporadic colon cancers showing low-level MSI were found to display higher rates of K-RAS mutations, MGMT promoter hypermethylation and a different genome-wide LOH profile than MSS colon carcinomas [41, 42] .
A comprehensive study of MSI in the pathogenesis of GBM including the investigation of the molecular alterations associated with MSI, the involvement of the MMR system as well as the relationship with the CIN-dependent events, has not been performed. Some reports analyzed MSI in glioblastomas either investigating small GBM series [43] [44] [45] [46] or using few microsatellite markers [47] . Contributing to this heterogeneous situation, different instability criteria and methods were used. We investigated MSI in 129 GBM patients (109 newly diagnosed, 20 relapses) with 15 polymorphic repeats as recommended by the National Cancer Institute [27] and observed MSI-L in 11 of 129 (8.5%) GBMs. Similarly to other sporadic MSI+ non-HNPCC non-colonic cancers such as gastric or endometrial carcinomas, the most sensitive markers were dinucleotides, larger repeats such as the tetranucleotide MYCL1 being only occasionally mutated.
Evaluating the clinicopathological tumor features by MSI status, we found that the incidence of MSI was more elevated in patients previously treated for an astrocytoma WHO grade II or III than in clinically de novo glioblastomas (12.5 vs. 6.5%, p = 0.18). This indicates a trend between MSI and progression of lower grade astrocytomas to GBM. Similarly, instability was observed to be more frequent in advanced than in early gastric cancers. Furthermore, MSI was evidenced in metastatic gastric cancers, but was absent in neighboring metaplastic epithelium [26] .
An aberrant MMR protein expression was found only in one MSI+ tumor, a giant-cell GBM. This subtype is a peculiar variant of ordinary GBM, making about 5% of the total [3, 48] . Interestingly, only the giant cell type showed these staining alterations, whereas the non-giant cell type harbored a positive staining. An inactivation of hMLH1 through mutation or promoter hypermethylation could not be found. Taking into account the histological characteristics of giant cell GBM, the possibility that hMLH1 mutations or hypermethylation of the hMLH1 promoter only affected the giant cell phenotype cannot be excluded. Alternatively, a transcriptional silencing concerning only the giant cells might also lead to this condition. The positive expression of MMR proteins in most of MSI+ tumors remarked the similarities between the MSI+ GBMs and the MSI+ gastric or endometrial carcinomas regarding instability pattern [49, 50] . This suggests that in most GBMs MSI might rather be explained by inactivation of minor MMR genes (for instance, hMSH3 or hPMS1), mutations leading to a dominant negative phenotype as reported for hPMS2 [51] or an imbalance in the relative amount of MMR proteins as shown for hMSH3 and hMSH6 [52] .
Glioblastoma cells may evade growth control mechanisms through CIN-dependent genetic changes such as aneuploidy, chromosome rearrangements and accumulation of somatic genetic mutations [53, 54] . Two CIN pathways were described in the pathogenesis of about 70% of GBMs, defining type 1 and type 2 GBM [5] [6] [7] . In the present analysis, 55% of the MSI+ tumors displayed a non-type 1, non-type 2 profile, whereas in the MSS control group such patterns were found in 27% of the cases. Nevertheless, since MSI was not observed in all non-type 1, non-type 2 GBM, further molecular alterations should be responsible for this GBM group. A negative association between mutations of p53 and MSI was observed and p53 mutations were detected only in one MSI+ giant cell GBM, which typically shows a higher rate of p53 mutations [48, 55] . Additionally, only missense p53 mutations were detected but not insertions/deletions at iterated bases, thus making the possibility that MSI caused p53 alterations unlikely. Similar results emerged from the analysis of MSI+ gastric carcinomas [19] . PTEN mutations in both primary and relapse GBMs were also found to be inversely associated with MSI. On the other hand, it was observed in GBM patients with Turcot syndrome and germline mutations of MMR genes that both p53 inactivation and chromosomal instability were present in the glioblastomas, but not in the metachronous colorectal carcinomas also developing in these patients [56] . Furthermore, none of the PTEN mutations in MSI+ tumors were observed in the polyadenine repeat of exon 8, a frequent target in MSI+ cancers. This finding distinguished the MSI pattern of GBMs from other MSI+ cancers, such as endometrial carcinomas, usually showing this type of PTEN mutation [15, 57] . Amplification of EGFR was more frequent in MSI+ relapses than in MSS recurrences. To our knowledge, such relationship has not been reported before.
Less is known about the timing of microsatellite instability in tumorigenesis. In the present study we detected a significantly higher MSI rate in relapses compared to primary tumors (25 vs. 5.5%, p = 0.027). Since all patients underwent radiotherapy after the first surgical procedure, a possible explanation is a radiation-induced damage in the mechanisms of DNA repair. However, by sequencing p53 and PTEN we did not find alterations such as base Martinez/Schackert/Plaschke/Baretton/ Appelt/Schackert pair deletions suggesting ionizing radiation-induced DNA damage. This is in accordance with previous observations in solid tumors developed after radiotherapy, in which high chromosomal instability but no MSI could be observed [58] .
The present analysis provides evidence that MSI and chromosomal instability in glioblastoma most likely follow independent pathways, as indicated by the inverse association between MSI and mutations of p53 and PTEN as well as the observed mutation types in these genes. The higher incidence of MSI in relapse GBMs might be compatible with a mutator phenotype that could predispose to the development of recurrences.
